About mavacamten
Cardiac myosin inhibitor
Used for
- Treats adults with symptomatic obstructive hypertrophic cardiomyopathy to improve symptoms and exercise ability.
Usual adult dose
Usually starts at 5 mg once daily; dose is adjusted using heart ultrasound monitoring, up to 15 mg daily.
Common side effects
- Dizziness
- Fainting
- Heart failure
- Reduced heart pumping function
Important warnings
- Can weaken heart pumping and cause serious heart failure; regular heart ultrasound monitoring is required.
- Do not use with pregnancy; effective contraception is needed during treatment and for four months afterward.
- Avoid starting or stopping interacting medicines without clinical review; some combinations raise heart-failure risk.
- Not established for children.
Pregnancy
Can harm an unborn baby. Avoid during pregnancy; use effective contraception during treatment and for four months after the final dose.
Breastfeeding
It is not known whether mavacamten passes into breast milk; discuss risks with a healthcare professional.
Interactions
- Strong CYP2C19 inhibitors, such as fluconazole, may increase mavacamten levels.
- Strong CYP2C19 inducers, such as rifampin, may reduce mavacamten levels.
- Some combinations with CYP2C9 or CYP3A4 inhibitors increase heart-failure risk.
- Other medicines that reduce heart contraction can increase heart-failure risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.